Reports Q2 revenue $1.94B, consensus $1.94B. “We delivered a strong Q2 – beating our expectations on both the top and bottom line, driven by customer demand for our suite of diversified products and solutions, as well as the strength and breadth of our international business,” said Ivan Tornos, Zimmer Biomet’s President and Chief Executive Officer. “Our performance demonstrates the progress we are making against our key priorities that support our long-range plan – people and culture, operational excellence, and innovation and diversification.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Signs Definitive Agreement to Acquire OrthoGrid Systems, Inc.
- Zimmer Biomet Announces Second Quarter 2024 Financial Results
- ZBH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Osstem Implant in advanced talks to buy ZimVie, Bloomberg reports
- Zimmer Biomet price target lowered to $117 from $130 at Truist